SCHEMBL806194

SCHEMBL806194

O=S(=O)(Nc1cccc(-c2nnn[nH]2)c1)c1ccc(Cl)c2nonc12

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 7/20 0.69
RORA P35398 1/20 0.46
RORC P51449 1/20 0.46
NR1H2 P55055 1/20 0.46
LNPEP Q9UIQ6 1/20 0.41
RAB9A P51151 1/20 0.38
PFKFB4 Q16877 2/20 0.38
LMNA P02545 2/20 0.37
NLRP3 Q96P20 1/20 0.37
HSPD1 P10809 1/20 0.37
PTPN2 P17706 1/20 0.37
PTPN1 P18031 1/20 0.37
PTPN5 P54829 1/20 0.37
HSPE1 P61604 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
KMT2A Q03164 1/20 0.37
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL793555 0.84 PFKFB3 (0.66) PFKFB3LNPEPRAB9APFKFB4LMNA
SCHEMBL794260 0.82 PFKFB3 (0.53) PFKFB3LNPEPRAB9ALMNAMAPT
SCHEMBL793284 0.82 ALDH1A1 (0.52) PFKFB3LNPEPRAB9AMAPTKMT2A
SCHEMBL21857311 0.82 PFKFB3 (1.00) PFKFB3LNPEPPFKFB4
SCHEMBL794311 0.82 PFKFB3 (0.65) PFKFB3LNPEPRAB9APFKFB4LMNA
SCHEMBL793409 0.81 PFKFB3 (0.55) PFKFB3LNPEPLMNATHRBKMT2A
SCHEMBL793856 0.80 PFKFB3 (0.67) PFKFB3LNPEPPFKFB4LMNATP53
SCHEMBL793550 0.79 MAPT (0.56) PFKFB3LNPEPLMNATP53MAPT
SCHEMBL793762 0.79 PFKFB3 (0.47) PFKFB3LNPEPLMNATP53MAPT
SCHEMBL792880 0.78 PFKFB3 (0.54) PFKFB3LNPEPLMNATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172339-A1 SULFONAMIDE COMPOUNDS SULT1A1, STS, ARSA PFKFB3 952/4885RORA 355/4885RORC 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.